EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Endotrophin as a biomarker and mediator in cardiovascular-kidney-metabolic syndrome: current insights and remaining questions

Federica Genovese iD, Morten Karsdal, Hanne Devos, Cecilie Bager, Julio Nuñez, Antoni Bayes-Genis

American Journal of Physiology-Cell Physiology · 2026

DOI: 10.1152/ajpcell.00769.2025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, 2026. Verfasst von Federica Genovese und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nordic Bioscience A/S, Herlev, Denmark. Hauptthemen laut MEDLINE: Metabolic Syndrome, Peptide Fragments, Cardio-Renal Syndrome, Kidney. Die Arbeit nennt 104 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endotrophin, a biologically active fragment derived from the α3 chain of collagen type VI, has emerged as both a risk biomarker and a potential pathogenic factor in cardiovascular-kidney-metabolic (CKM) syndrome. Over the past decade, research has shed light on its role in various noncommunicable diseases, emphasizing its signaling properties and diagnostic potential. Despite these advances, significant gaps remain in our understanding of how endotrophin contributes to CKM pathophysiology and whether targeting it therapeutically could modify disease progression. This narrative review synthesizes current evidence on endotrophin biological functions and clinical associations, drawing from both experimental and clinical studies. In addition, it identifies critical areas where further investigation is required, including the molecular mechanisms linking endotrophin to CKM-related tissue dysfunction and its causal role in disease development. By mapping current knowledge and highlighting research priorities, this review aims to advance the field toward a more complete understanding of endotrophin as a potential therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromePeptide FragmentsCardio-Renal SyndromeKidneyCollagen Type VICardiovascular DiseasesHumansBiomarkersAnimals

Stichwörter der Autor:innen

CKMbiomarkerendotrophinextracellular matrixfibrosis

Substanzen

BiomarkersendotrophinPeptide FragmentsCollagen Type VI

Autor:innen und Institutionen

  • Nordic Bioscience A/S, Herlev, Denmark.
  • Cardiology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • INCLIVA, CIBER Cardiovascular, Universidad de Valencia, Valencia, Spain.
  • Heart Institute, University Hospital Germans Trias i Pujol, Badalona, Spain.
  • Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.

ORCID-Profile: Federica Genovese

Zitieren

APA

Genovese, F., Karsdal, M., Devos, H., Bager, C., Nuñez, J., & Bayes-Genis, A. (2026). Endotrophin as a biomarker and mediator in cardiovascular-kidney-metabolic syndrome: current insights and remaining questions. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00769.2025

Vancouver

Genovese F, Karsdal M, Devos H, Bager C, Nuñez J, Bayes-Genis A. Endotrophin as a biomarker and mediator in cardiovascular-kidney-metabolic syndrome: current insights and remaining questions. American Journal of Physiology-Cell Physiology. 2026. doi:10.1152/ajpcell.00769.2025

BibTeX
@article{Genovese2026,
  author = {Genovese, Federica and Karsdal, Morten and Devos, Hanne and Bager, Cecilie and Nuñez, Julio and Bayes-Genis, Antoni},
  title = {Endotrophin as a biomarker and mediator in cardiovascular-kidney-metabolic syndrome: current insights and remaining questions},
  journal = {American Journal of Physiology-Cell Physiology},
  year = {2026},
  doi = {10.1152/ajpcell.00769.2025}
}
Kostenlos starten →